Clinical considerations for treatment and prophylaxis of mpox infection in people who are immunocompromised

Details

• Alternative Title:
  Clinical considerations for treatment and prophylaxis of monkeypox virus infection in people with HIV
• Corporate Authors:
  National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of High-Consequence Pathogens and Pathology.
• Description:
  Updated January 4, 2023
  
  Updates as of December 13, 2022: Expanded to include considerations for treatment and prophylaxis of mpox virus infection in people with immunocompromising conditions other than HIV.
  
  Who this is for: Healthcare professionals caring for people who are immunocompromised from HIV or other conditions or who are taking immunosuppressive agents.
  
  What this is for: Issues to consider when caring for people with or exposed to mpox who are also immunocompromised from a condition or from an immunosuppressive drug.
  
  How to use: This information may be used to educate staff at healthcare facilities and by healthcare professionals developing mpox treatment and prophylaxis plans for people who have HIV or are immunocompromised or immunosuppressed from other conditions or treatments.
  
  CDC is updating webpages with the term "mpox" to reduce stigma and other issues associated with prior terminology. This change is aligned with the recent World Health Organization decision.
  
  
• Content Notes:
  Mpox in People Who are Immunocompromised -- Diagnosis -- Treatment -- Vaccination.
• Subjects:
  Disease Management HIV Infections Mpox (monkeypox) Mpox (monkeypox)/therapy
• Document Type:
  Webpage
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha256:4e5efcd41852b6df7bee8b13d4116d9b060303686c23cddca38ddb6245582881
• Download URL:
  https://stacks.cdc.gov/view/cdc/123269/cdc_123269_DS1.pdf
• File Type:
  [PDF - 474.88 KB ]